Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sevelamer Clear all
Completed Early Phase 1 Interventional

Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease

NCT01308242
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer Carbonate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

NCT03824587
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Phosphate Binder Agents
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

NCT03427125
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
The Bronx, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 1 Interventional

Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy

NCT00967629
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sevelamer Carbonate, Calcium Carbonate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

NCT00875017
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Lanthanum Carbonate, Sevelamer
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 2, 2026, 9:14 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Head to Head Study Against Sevelamer Hydrochloride

NCT00441545
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5
Interventions
Fosrenol (Lanthanum Carbonate), Sevelamer hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 2, 2026, 9:14 PM EDT
Terminated Phase 4 Interventional

Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

NCT01277497
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer carbonate, Calcium acetate
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

The Effects of Sevelamer Carbonate on Diabetic Nephropathy

NCT01493050
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sevelamer Carbonate, calcium carbonate
Drug
Lead sponsor
Gary Striker
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers

NCT00925704
View directory record Official record
Conditions
Healthy
Interventions
Calcitriol, Lanthanum carbonate + Calcitriol, Sevelamer carbonate + Calcitriol
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

NCT01574326
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
Placebo, Sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 18 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

NCT02127125
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Maltodextrin, Synbiotic, Sevelamer
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

NCT01324128
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate, PA21-1 (1.25 g tablet containing 250 mg iron)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 2, 2026, 9:14 PM EDT
Not listed Phase 4 Interventional

How Bone is Made in Children Receiving Dialysis

NCT01799317
View directory record Official record
Conditions
Bone Mineralization Defect
Interventions
Vitamin D2
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Loma Linda, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

NCT02346890
View directory record Official record
Conditions
Healthy
Interventions
AZD1722, Renvela
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 2, 2026, 9:14 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

NCT00844662
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Fermagate, Sevelamer hydrochloride
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Hot Springs, Arkansas • Bakersfield, California • Lynwood, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 2, 2026, 9:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 2, 2026, 9:14 PM EDT
Terminated Not applicable Interventional Results available

The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

NCT01238588
View directory record Official record
Conditions
Dialysis, Cardiovascular Disease, Atherosclerosis, Inflammation, Hyperphosphatemia
Interventions
Sevelamer Carbonate (Renvela)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Boston, Massachusetts • Framingham, Massachusetts • Marlborough, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

NCT01191255
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Failure
Interventions
ferric citrate, ca acetate, sevelamer carbonate, placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
52
States / cities
Tempe, Arizona • Los Angeles, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

NCT03988920
View directory record Official record
Conditions
Hyperphosphatemia, End Stage Renal Disease
Interventions
Tenapanor, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

NCT02124759
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Sevelamer, Synbiotic, Maltodextrin, High Fat diet, Low Fat diet
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Phase 3 Interventional

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

NCT00268957
View directory record Official record
Conditions
Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
Interventions
Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
29
States / cities
Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 2, 2026, 9:14 PM EDT
Completed Not applicable Interventional Results available

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

NCT00999037
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Sevelamer Carbonate, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 2, 2026, 9:14 PM EDT